Joyeeta Mukherjee
Research Subjects
Joyeeta Mukherjee has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alok Gangaramany
Final Mile Consulting, New York, New York, 10007
3 shared publications - Venkatesan Chakrapani
Centre for Sexuality and Health Research and Policy (C-SHaRP), India; The Humsafar Trust, Mumbai, India; School of Social Sciences, National Institute of Advanced Studies (NIAS), Bengaluru, India
3 shared publications - Aylur Kailasom Srikrishnan
YR Gaitonde Centre for AIDS Research and Education, Chennai, India
2 shared publications - Margaret Keane
International AIDS Vaccine Initiative, New York, NY, United States
2 shared publications - Pallavi Manchi
The Final Mile, Mumbai, India
2 shared publications - Pratyasha Rath
The Final Mile, Mumbai, India
2 shared publications
Latest Publications
- Open Access
- 21 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0321725
Acceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention among vulnerable populations in India: Findings from a qualitative study
With newer advances in HIV biomedical research, the prevention toolbox is expanding with potential inclusion of long-acting anti-retrovirals, broadly neutralizing antibodies (bNAbs), and vaccines. While a multitude of prevention options provide diverse choice sets, they may potentially introduce conundrums and trade-offs which influence end-user decisions on acceptability. Thus, to maximize the unique value and uptake of new products, it is critical to understand contextual drivers of choice and relative product positioning. With HIV bNAbs in the pipeline, a qualitative study was conducted to understand end-users’ acceptability. 36 focus-group discussions (n=242) and 57 in-depth interviews were conducted in Chennai, Delhi and Mumbai, with female sex workers (FSWs), men who have sex with men (MSM), people who inject drugs (PWID) and transgender women (TGW) and adolescent girls and young women (AGYW). In addition, 15 simulated behavioral experiments (n=94) were conducted to delve deeper into factors influencing decision-making and potential avenues for intention-action gaps to understand preference construction and reversal pathways. Efficacy, frequency of administration and side-effects were the most important attributes driving acceptability. At least 70% to 90% efficacy was preferred. Arm was the most preferred site of administration (familiarity, maximum privacy), whereas buttocks were preferred by some (better pain tolerance, unhampered mobility). One injection every 3–6 months from community-based facilities was most preferred. Most did not favor self-administration (lack of self-efficacy, adverse events) and voiced confidence in community-friendly professionals. Concerns were raised about potential major side-effects such as interactions with co-morbidities, fertility, pregnancy, gender-affirmation therapy, physical appearance. When end-users were presented with hypothetical product profiles, all preferred the non-antiretroviral (non-ARV) based option which had arm as site of injection and administered every three months by healthcare workers. The preference construction journey revealed positive emotions and rational considerations which favoured bNAbs use but they were contrasted with negative emotions and rationale which hindered acceptability, and the users were faced with multiple conundrums. Some of these conundrums gave rise to potential scenarios of preference reversal.
- 21 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0321725
Open AccessAcceptability of broadly neutralizing antibodies (bNAbs) for HIV prevention among vulnerable populations in India: Findings from a qualitative study
With newer advances in HIV biomedical research, the prevention toolbox is expanding with potential inclusion of long-acting anti-retrovirals, broadly neutralizing antibodies (bNAbs), and vaccines. While a multitude of prevention options provide diverse choice sets, they may potentially introduce conundrums and trade-offs which influence end-user decisions on acceptability. Thus, to maximize the unique value and uptake of new products, it is critical to understand contextual drivers of choice and relative product positioning. With HIV bNAbs in the pipeline, a qualitative study was conducted to understand end-users’ acceptability. 36 focus-group discussions (n=242) and 57 in-depth interviews were conducted in Chennai, Delhi and Mumbai, with female sex workers (FSWs), men who have sex with men (MSM), people who inject drugs (PWID) and transgender women (TGW) and adolescent girls and young women (AGYW). In addition, 15 simulated behavioral experiments (n=94) were conducted to delve deeper into factors influencing decision-making and potential avenues for intention-action gaps to understand preference construction and reversal pathways. Efficacy, frequency of administration and side-effects were the most important attributes driving acceptability. At least 70% to 90% efficacy was preferred. Arm was the most preferred site of administration (familiarity, maximum privacy), whereas buttocks were preferred by some (better pain tolerance, unhampered mobility). One injection every 3–6 months from community-based facilities was most preferred. Most did not favor self-administration (lack of self-efficacy, adverse events) and voiced confidence in community-friendly professionals. Concerns were raised about potential major side-effects such as interactions with co-morbidities, fertility, pregnancy, gender-affirmation therapy, physical appearance. When end-users were presented with hypothetical product profiles, all preferred the non-antiretroviral (non-ARV) based option which had arm as site of injection and administered every three months by healthcare workers. The preference construction journey revealed positive emotions and rational considerations which favoured bNAbs use but they were contrasted with negative emotions and rationale which hindered acceptability, and the users were faced with multiple conundrums. Some of these conundrums gave rise to potential scenarios of preference reversal.
- Open Access
- 7 February 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e47700
Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study
Background: Acceptability and preference research play a crucial role in the design, evaluation, and implementation of any new prevention product in any geographical setting. They also play a critical role in the development of clinical guidelines and policies. A wide range of acceptability studies have been conducted in diverse general and key populations for various new HIV prevention products worldwide. As clinical development strategies are being developed for clinical studies of broadly neutralizing antibodies (bNAbs) as potential HIV prevention products, appropriately tailoring them to address the type of HIV epidemic at hand would be critical for efficient uptake within in-country public health systems and decrease adoption and adherence challenges. Accomplishing this will require comprehensive acceptability and feasibility studies to inform multisectoral efforts that increase access to these products and national policies supportive of access to health care for those in most need. Thus, it is both opportune and important to undertake focused efforts toward informing product development strategies. Objective: This study aims to understand preferences for product attributes and key behavioral factors influencing adoption and uptake of bNAb prevention products among end-users including female sex workers, men who have sex with men, transgender women, people who inject drugs, and adolescent girls and young women in India and understand the key health system and programmatic perspectives toward the introduction of bNAb prevention products from health service providers and policy makers in India. Methods: A multisite study will be conducted in Delhi, Mumbai, and Chennai to capture the differences in perspectives among diverse end-users and key informants across the country. The study will use a multimethods design using focus group discussions, in-depth interviews, simulated behavioral experiments, and key informant interviews. A total of 30 focus group discussions, 45 in-depth interviews, 15 simulated behavioral experiments sessions, and 15 key informant interviews will be conducted across 3 sites. Results: The data collected and analyzed will enable insights on which specific product attributes matter the most to the populations and why some attributes are less preferred; contextual drivers of preferences and choices at individual, interpersonal, social, and structural levels; and relative positioning of bNAb products among other potential HIV prevention products. Insights from the health service providers and policy makers will provide a critical understanding of the need perception of the potential product in the existing product landscape and what additional efforts and resources are required for potential introduction, delivery, and uptake of the bNAb products in the Indian context. Conclusions: Insights generated from the abovementioned objectives will represent perspectives of populations of interest across geographies in India, will provide an overview of the acceptability of bNAb products and the feasibility of their introduction in this region, and will inform product development strategies. International Registered Report Identifier (IRRID): DERR1-10.2196/47700
- 7 February 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e47700
Open AccessUnderstanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study
Background: Acceptability and preference research play a crucial role in the design, evaluation, and implementation of any new prevention product in any geographical setting. They also play a critical role in the development of clinical guidelines and policies. A wide range of acceptability studies have been conducted in diverse general and key populations for various new HIV prevention products worldwide. As clinical development strategies are being developed for clinical studies of broadly neutralizing antibodies (bNAbs) as potential HIV prevention products, appropriately tailoring them to address the type of HIV epidemic at hand would be critical for efficient uptake within in-country public health systems and decrease adoption and adherence challenges. Accomplishing this will require comprehensive acceptability and feasibility studies to inform multisectoral efforts that increase access to these products and national policies supportive of access to health care for those in most need. Thus, it is both opportune and important to undertake focused efforts toward informing product development strategies. Objective: This study aims to understand preferences for product attributes and key behavioral factors influencing adoption and uptake of bNAb prevention products among end-users including female sex workers, men who have sex with men, transgender women, people who inject drugs, and adolescent girls and young women in India and understand the key health system and programmatic perspectives toward the introduction of bNAb prevention products from health service providers and policy makers in India. Methods: A multisite study will be conducted in Delhi, Mumbai, and Chennai to capture the differences in perspectives among diverse end-users and key informants across the country. The study will use a multimethods design using focus group discussions, in-depth interviews, simulated behavioral experiments, and key informant interviews. A total of 30 focus group discussions, 45 in-depth interviews, 15 simulated behavioral experiments sessions, and 15 key informant interviews will be conducted across 3 sites. Results: The data collected and analyzed will enable insights on which specific product attributes matter the most to the populations and why some attributes are less preferred; contextual drivers of preferences and choices at individual, interpersonal, social, and structural levels; and relative positioning of bNAb products among other potential HIV prevention products. Insights from the health service providers and policy makers will provide a critical understanding of the need perception of the potential product in the existing product landscape and what additional efforts and resources are required for potential introduction, delivery, and uptake of the bNAb products in the Indian context. Conclusions: Insights generated from the abovementioned objectives will represent perspectives of populations of interest across geographies in India, will provide an overview of the acceptability of bNAb products and the feasibility of their introduction in this region, and will inform product development strategies. International Registered Report Identifier (IRRID): DERR1-10.2196/47700
- Open Access
- 29 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Understanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study (Preprint)
BACKGROUND Acceptability and preference research play a crucial role in the design, evaluation, and implementation of any new prevention product in any geographical setting. They also play a critical role in the development of clinical guidelines and policies. A wide range of acceptability studies have been conducted in diverse general and key populations for various new HIV prevention products worldwide. As clinical development strategies are being developed for clinical studies of broadly neutralizing antibodies (bNAbs) as potential HIV prevention products, appropriately tailoring them to address the type of HIV epidemic at hand would be critical for efficient uptake within in-country public health systems and decrease adoption and adherence challenges. Accomplishing this will require comprehensive acceptability and feasibility studies to inform multisectoral efforts that increase access to these products and national policies supportive of access to health care for those in most need. Thus, it is both opportune and important to undertake focused efforts toward informing product development strategies. OBJECTIVE This study aims to understand preferences for product attributes and key behavioral factors influencing adoption and uptake of bNAb prevention products among end-users including female sex workers, men who have sex with men, transgender women, people who inject drugs, and adolescent girls and young women in India and understand the key health system and programmatic perspectives toward the introduction of bNAb prevention products from health service providers and policy makers in India. METHODS A multisite study will be conducted in Delhi, Mumbai, and Chennai to capture the differences in perspectives among diverse end-users and key informants across the country. The study will use a multimethods design using focus group discussions, in-depth interviews, simulated behavioral experiments, and key informant interviews. A total of 30 focus group discussions, 45 in-depth interviews, 15 simulated behavioral experiments sessions, and 15 key informant interviews will be conducted across 3 sites. RESULTS The data collected and analyzed will enable insights on which specific product attributes matter the most to the populations and why some attributes are less preferred; contextual drivers of preferences and choices at individual, interpersonal, social, and structural levels; and relative positioning of bNAb products among other potential HIV prevention products. Insights from the health service providers and policy makers will provide a critical understanding of the need perception of the potential product in the existing product landscape and what additional efforts and resources are required for potential introduction, delivery, and uptake of the bNAb products in the Indian context. CONCLUSIONS Insights generated from the abovementioned objectives will represent perspectives of populations of interest across geographies in India, will provide an overview of the acceptability of bNAb products and the feasibility of their introduction in this region, and will inform product development strategies. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/47700
- 29 May 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessUnderstanding the Acceptability of Broadly Neutralizing Antibodies for HIV Prevention Among At-Risk Populations and Feasibility Considerations for Product Introduction in India: Protocol for a Qualitative Study (Preprint)
BACKGROUND Acceptability and preference research play a crucial role in the design, evaluation, and implementation of any new prevention product in any geographical setting. They also play a critical role in the development of clinical guidelines and policies. A wide range of acceptability studies have been conducted in diverse general and key populations for various new HIV prevention products worldwide. As clinical development strategies are being developed for clinical studies of broadly neutralizing antibodies (bNAbs) as potential HIV prevention products, appropriately tailoring them to address the type of HIV epidemic at hand would be critical for efficient uptake within in-country public health systems and decrease adoption and adherence challenges. Accomplishing this will require comprehensive acceptability and feasibility studies to inform multisectoral efforts that increase access to these products and national policies supportive of access to health care for those in most need. Thus, it is both opportune and important to undertake focused efforts toward informing product development strategies. OBJECTIVE This study aims to understand preferences for product attributes and key behavioral factors influencing adoption and uptake of bNAb prevention products among end-users including female sex workers, men who have sex with men, transgender women, people who inject drugs, and adolescent girls and young women in India and understand the key health system and programmatic perspectives toward the introduction of bNAb prevention products from health service providers and policy makers in India. METHODS A multisite study will be conducted in Delhi, Mumbai, and Chennai to capture the differences in perspectives among diverse end-users and key informants across the country. The study will use a multimethods design using focus group discussions, in-depth interviews, simulated behavioral experiments, and key informant interviews. A total of 30 focus group discussions, 45 in-depth interviews, 15 simulated behavioral experiments sessions, and 15 key informant interviews will be conducted across 3 sites. RESULTS The data collected and analyzed will enable insights on which specific product attributes matter the most to the populations and why some attributes are less preferred; contextual drivers of preferences and choices at individual, interpersonal, social, and structural levels; and relative positioning of bNAb products among other potential HIV prevention products. Insights from the health service providers and policy makers will provide a critical understanding of the need perception of the potential product in the existing product landscape and what additional efforts and resources are required for potential introduction, delivery, and uptake of the bNAb products in the Indian context. CONCLUSIONS Insights generated from the abovementioned objectives will represent perspectives of populations of interest across geographies in India, will provide an overview of the acceptability of bNAb products and the feasibility of their introduction in this region, and will inform product development strategies. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/47700